Overview: Nerve Biopsy Panel TestIntroduction: The Nerve Biopsy Panel Test analyzes nerve tissue to diagnose neuropathy, causing numbness or tingling. Following 2023 AAN guidelines, it uses histopathology for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected peripheral neuropathy, such as CIDP or vasculitic neuropathy.
Other Names: Nerve Biopsy Assay, Neuropathy Tissue Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Nerve biopsy testing began in the 1970s with neuropathy research. Histopathology methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Analyzes nerve tissue to diagnose neuropathy, guides treatment, and evaluates patients with numbness or tingling.
Test Parameters: 1. Nerve Tissue Analysis
Pretest Condition: No fasting required. Collect tissue. Report history of numbness, tingling, or neuropathic symptoms.
Specimen: Tissue (sterile container, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document numbness, tingling, weakness, or history of autoimmune or metabolic diseases. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, neuropathy implications, and risks of biopsy.
Procedural Considerations: Uses histopathology to analyze nerve tissue for neuropathy. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neuropathy diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or low sample quality can affect results. Contamination may reduce specificity.
Clinical Significance: Abnormal nerve tissue findings confirm neuropathy, guiding immunosuppressive or supportive therapy. Normal findings may require further testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: Nerve conduction studies, EMG, or antibody testing (e.g., anti-MAG IgM) to confirm neuropathy diagnosis.
Test Limitations: Invasive procedure; not all neuropathies show clear biopsy findings. Clinical correlation is needed.
References: AAN Neuropathy Guidelines, 2023; Neurology, England JD, 2022.
